USFDA Inspection: Alembic Pharma gets form 483 with 5 procedural observations for Gujarat plant
The US Food and Drug Administration (USFDA) conducted inspection at Jarod-based solid oral formulation facility.;
Advertisement
New Delhi: Alembic Pharmaceuticals on Saturday said the US health regulator has issued Form 483 with five observations after inspecting its Gujarat-based manufacturing plant.
The US Food and Drug Administration (USFDA) conducted inspection at Jarod-based solid oral formulation facility from November 14-22, 2024, the drug firm said in a regulatory filing.
Also Read: Alembic Pharma successfully completes USFDA inspection at Panelav Oncology formulation facility
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.